Dengue virus (DENV) is a mosquito-transmitted RNA virus responsible for 390 million infections each year and significant morbidity and mortality throughout tropical and subtropical regions of the world. Efforts to develop a DENV vaccine span 70 years and include the work of luminaries of the virus vaccine field. Although vaccines have been used to reduce the global health burden of other flaviviruses, the unique requirement for a single vaccine to protect against four different groups of dengue viruses, and the link between secondary infections and DENV disease pathogenesis, has limited success to date. In this review, we discuss several promising DENV vaccine candidates in clinical trials and assess how recent advances in understanding of DENV biology and immunity may expedite efforts toward the development of safe and effective vaccines.

中文翻译：

---

疫苗开发作为控制登革热病毒发病机制的手段：我们知道足够了吗？

登革热病毒（DENV）是一种由蚊子传播的RNA病毒，每年引起3.9亿例感染，在世界热带和亚热带地区的发病率和死亡率都很高。开发DENV疫苗的努力跨越了70年，其中包括病毒疫苗领域的杰出人士。尽管已经使用疫苗来减轻其他黄病毒的总体健康负担，但是迄今为止，对单一疫苗的独特需求是能够抵御四组不同的登革热病毒，以及继发感染与DENV疾病发病机制之间的联系，迄今取得的成功有限。在这篇综述中，我们将在临床试验中讨论几种有前途的DENV疫苗候选物，并评估对DENV生物学和免疫性的最新了解如何促进开发安全有效疫苗的努力。